For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Sales and marketing | - | 0 | ||
| Research and development | 785,608 | 889,896 | ||
| General and administrative | 831,339 | 1,095,465 | ||
| Total operating expenses | 1,616,947 | 1,985,361 | ||
| Operating loss | -1,616,947 | -1,985,361 | ||
| Interest expense | 200 | 222 | ||
| Interest income | 18,961 | 29,254 | ||
| Other income, net | 554 | -275 | ||
| Total other income (expense), net | 19,315 | 28,757 | ||
| Net loss | -1,597,632 | -1,956,604 | ||
| Net loss applicable to common stockholders | -1,597,632 | - | ||
| Basic EPS | -1.01 | -1.41 | ||
| Diluted EPS | -1.01 | -1.41 | ||
| Basic Average Shares | 1,574,535 | 1,387,118 | ||
| Diluted Average Shares | 1,574,535 | 1,387,118 | ||
Bluejay Diagnostics, Inc. (BJDX)
Bluejay Diagnostics, Inc. (BJDX)